PREVALENCE AND CLINICAL SIGNIFICANCE OF IRON DEICIENCY IN PATIENTS WITH ACUTE DECOMPENSATED HEART FAILURE: RESULTS OF A SINGLE-CENTER COHORT STUDY
Open Access
- 4 May 2026
- journal article
- Published by NII KPSSZ in Complex Issues of Cardiovascular Diseases
- Vol. 15 (2) , 6-16
Abstract
Highlights Iron deficiency is one of the most common comorbidities in heart failure, associated with a negative prognosis; however, the significance of iron deficiency in patients with acute decompensated heart failure remains uncertain. The obtained results allowed us to expand the profile of patients with acute decompensated heart failure and evaluate the contribution of iron deficiency to the course of the disease and the long-term prognosis of patients. Aim . To determine the prevalence of iron deficiency (ID), to assess its clinical and prognostic significance, and its impact on one-year outcomes in patients with acute decompensated heart failure, based on data from a single-center cohort study. Methods. This prospective cohort study consecutively (from January 1, 2023 to January 1, 2024) included 812 patients admitted with acute decompensated heart failure. The observation period was from January 1, 2023 to January 1, 2025, inclusive. The median age was 72 [57; 83] years. Results. The clinical phenotypes of patients with ADHF were predominantly represented by an ischemic origin of heart failure. All patients with ADHF had a high prevalence of hypertension and a high Charlson comorbidity index. It was found that patients with ID had significantly higher NT-proBNP values than patients without ID: 2810.8 [1 783.6; 4 198.3] versus 1 981.2 [1 221.5; 3 241.7] pg/ml. Patients with ID had a higher prevalence of major underlying diseases: type 2 diabetes (n = 181, 37.0% vs n = 102, 31.5%; p < 0.05), obesity (n = 378, 77.3% vs n = 170, 52.6%, p < 0.05), CKD (n = 263, 53.9% vs n = 144, 44.5%, p < 0.05); as well as older age (76 [54; 83] vs 69 [47; 79] years). The total number of adverse events was higher in the group of patients with ID. Conclusions. The prevalence of iron deficiency in patients with ADHF was 60%. Patients with ID were characterized by older age, a high prevalence of type 2 diabetes, obesity, and CKD, as well as a greater number of adverse events during the long-term follow-up period.Keywords
This publication has 17 references indexed in Scilit:
- 2023 Updated European Society of Cardiology guidelines on heart failureRussian Journal of Cardiology, 2024
- Prevalence and clinical significance of iron deficiency in patients with acute decompensated heart failureRussian Journal of Cardiology, 2023
- Factors associated with iron deficiency in heart failureCardiovascular Therapy and Prevention, 2023
- Acute Heart Failure and Iron Deficiency: A Prospective, Multicentre, Observational StudyESC Heart Failure, 2021
- Neurohormonal activation induces intracellular iron deficiency and mitochondrial dysfunction in cardiac cellsCell & Bioscience, 2021
- Iron deficiency and short-term adverse events in patients with decompensated heart failureClinical Research in Cardiology, 2021
- 2020 Clinical practice guidelines for Chronic heart failureRussian Journal of Cardiology, 2020
- Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart AssociationCirculation, 2020
- Association Between Norepinephrine Levels and Abnormal Iron Status in Patients With Chronic Heart Failure: Is Iron Deficiency More Than a Comorbidity?Journal of the American Heart Association, 2019
- Ferritin Levels and Risk of Heart Failure—the Atherosclerosis Risk in Communities StudyEuropean Journal of Heart Failure, 2016